Biomea FusionBMEA
BMEA
About: Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
Employees: 106
0
Funds holding %
of 7,407 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
167% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 12
56% more call options, than puts
Call options by funds: $11.9M | Put options by funds: $7.66M
22% more funds holding
Funds holding: 87 [Q3] → 106 (+19) [Q4]
7% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 27
0% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]
1.06% less ownership
Funds ownership: 64.32% [Q3] → 63.26% (-1.06%) [Q4]
62% less capital invested
Capital invested by funds: $235M [Q3] → $89M (-$146M) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$3
85%
upside
Avg. target
$19.67
1,114%
upside
High target
$40
2,369%
upside
3 analyst ratings
2 positive
67%
1 neutral
33%
0 negative
0%
Barclays Peter Lawson 0% 1-year accuracy 0 / 21 met price target | 85%upside $3 | Equal-Weight Maintained | 2 Apr 2025 |
HC Wainwright & Co. Joseph Pantginis 12% 1-year accuracy 52 / 424 met price target | 2,369%upside $40 | Buy Reiterated | 1 Apr 2025 |
D. Boral Capital Jason Kolbert 15% 1-year accuracy 52 / 346 met price target | 888%upside $16 | Buy Maintained | 24 Mar 2025 |
Financial journalist opinion
Based on 7 articles about BMEA published over the past 30 days
Negative
Zacks Investment Research
1 week ago
After Plunging -27.9% in 4 Weeks, Here's Why the Trend Might Reverse for Biomea Fusion (BMEA)
Biomea Fusion (BMEA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Neutral
GlobeNewsWire
1 week ago
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that on March 23, 2025, the compensation committee of Biomea's board of directors granted two new employees non-qualified stock options to purchase an aggregate of 30,000 shares of the Company's common stock. The shares underlying each employee's stock options will vest 1/16 on a quarterly basis over four years, in each case subject to each such employee's continued employment with the Company on such vesting dates. All of the above-described awards were made under Biomea's 2023 Inducement Equity Plan (the “Plan”).
Negative
Zacks Investment Research
1 week ago
After Plunging -19.32% in 4 Weeks, Here's Why the Trend Might Reverse for Biomea Fusion (BMEA)
Biomea Fusion (BMEA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Neutral
GlobeNewsWire
2 weeks ago
Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights
REDWOOD CITY, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, reported fourth quarter and full year 2024 financial results and corporate highlights.
Negative
Zacks Investment Research
2 weeks ago
After Plunging -20.42% in 4 Weeks, Here's Why the Trend Might Reverse for Biomea Fusion (BMEA)
The heavy selling pressure might have exhausted for Biomea Fusion (BMEA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Neutral
GlobeNewsWire
2 weeks ago
Biomea Fusion Announces Leadership Transition
Board member Mick Hitchcock, named interim CEO replacing Thomas Butler. COO and President Ramses Erdtmann continuing at Biomea in current role.
Neutral
GlobeNewsWire
3 weeks ago
Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-cell Function with a 53% Mean Increase in C-peptide Levels 3 Months After Last Dose
REDWOOD CITY, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced the presentation of preclinical and clinical data from studies assessing icovamenib at the Advanced Technologies & Treatments for Diabetes (ATTD) 2025 Conference in Amsterdam, The Netherlands. The new findings support icovamenib's potential as a first-in-class, disease-modifying therapy by targeting beta-cell restoration, enhancing insulin secretion, and sustaining glycemic improvements beyond icovamenib's treatment period.
Neutral
GlobeNewsWire
1 month ago
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that on March 3, 2025, the compensation committee of Biomea's board of directors granted one new employee non-qualified stock options to purchase an aggregate of 25,000 shares of the Company's common stock. The shares underlying the employee's stock options will vest 1/16 on a quarterly basis over four years, subject to the employee's continued employment with the Company on such vesting dates. The above-described award was made under Biomea's 2023 Inducement Equity Plan (the “Plan”).
Neutral
GlobeNewsWire
1 month ago
Biomea Fusion to Unveil New Icovamenib Data at the 18th International Conference on Advanced Technologies & Treatments for Diabetes
REDWOOD CITY, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that it will feature two oral presentations, one poster presentation, and chair a symposium at the 18th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2025).
Negative
Benzinga
3 months ago
Why Is Diabetes-Drug Developer Biomea Fusion Stock Trading Lower On Tuesday?
On Tuesday, Biomea Fusion Inc. BMEA revealed topline results from the ongoing COVALENT-111 study of icovamenib in patients with type 2 diabetes (T2D).
Charts implemented using Lightweight Charts™